In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor.

[1]  Jun Yang,et al.  Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease. , 2012, American journal of respiratory cell and molecular biology.

[2]  Sampathkumar Anandan,et al.  Pharmacokinetics and Pharmacodynamics of AR9281, an Inhibitor of Soluble Epoxide Hydrolase, in Single‐ and Multiple‐Dose Studies in Healthy Human Subjects , 2012, Journal of clinical pharmacology.

[3]  S. Rennard,et al.  PDE4: A Novel Target in the Treatment of Chronic Obstructive Pulmonary Disease , 2012, Clinical pharmacology and therapeutics.

[4]  Hermes Licea-Perez,et al.  Development of a semi-automated LC/MS/MS method for the simultaneous quantitation of 14,15-epoxyeicosatrienoic acid, 14,15-dihydroxyeicosatrienoic acid, leukotoxin and leukotoxin diol in human plasma as biomarkers of soluble epoxide hydrolase activity in vivo. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[5]  S. Simon,et al.  The anti-inflammatory effects of soluble epoxide hydrolase inhibitors are independent of leukocyte recruitment. , 2011, Biochemical and biophysical research communications.

[6]  B. Hammock,et al.  Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP , 2011, Proceedings of the National Academy of Sciences.

[7]  R. Ames,et al.  Development of a High Throughput Cell-Based Assay for Soluble Epoxide Hydrolase Using BacMam Technology , 2010, Molecular biotechnology.

[8]  Baoguang Zhao,et al.  Design, synthesis and selection of DNA-encoded small-molecule libraries. , 2009, Nature chemical biology.

[9]  O. Harrison,et al.  Airway infiltration of CD4+ CCR6+ Th17 type cells associated with chronic cigarette smoke induced airspace enlargement. , 2008, Immunology letters.

[10]  A. A. Spector,et al.  Action of epoxyeicosatrienoic acids on cellular function. , 2007, American journal of physiology. Cell physiology.

[11]  D. Bundschuh,et al.  Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors. , 2006, Pulmonary pharmacology & therapeutics.

[12]  M. Clare-Salzler,et al.  Eicosanoid Imbalance in the NOD Mouse Is Related to a Dysregulation in Soluble Epoxide Hydrolase and 15‐PGDH Expression , 2005, Annals of the New York Academy of Sciences.

[13]  B. Hammock,et al.  Soluble epoxide hydrolase is a therapeutic target for acute inflammation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[14]  R. Shohet,et al.  Tobacco smoke dysregulates endothelial vasoregulatory transcripts in vivo. , 2005, Physiological genomics.

[15]  Kevin R. Smith,et al.  Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  B. Hammock,et al.  Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. , 2005, Annual review of pharmacology and toxicology.

[17]  B. Hammock,et al.  Metabolism of monoepoxides of methyl linoleate: bioactivation and detoxification. , 2000, Archives of biochemistry and biophysics.

[18]  K. Ley,et al.  Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. , 1999, Science.

[19]  P. Pratt,et al.  Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. , 1996, Circulation research.

[20]  M. Rosolowsky,et al.  Role of PGI2 and epoxyeicosatrienoic acids in relaxation of bovine coronary arteries to arachidonic acid. , 1993, The American journal of physiology.